Financial Data and Key Metrics Changes - MaxCyte reported record revenue of $11.6 million for Q1 2022, representing a 78% increase compared to $6.5 million in Q1 2021 [7][13] - Core business revenue was $9.6 million, up from $6.5 million year-over-year, with a gross margin of 91%, an increase from 89% in the prior year [14][15] - The company recognized $2 million in SPL program-related revenue in Q1 2022, compared to immaterial revenue in Q1 2021 [14] Business Line Data and Key Metrics Changes - Revenue from cell therapy customers grew 57% year-over-year to $7.4 million, while revenue from drug discovery customers increased by 23% to $2.2 million [13][7] - The core cell-engineering business saw a robust performance, with a 48% year-over-year growth [6] Market Data and Key Metrics Changes - The company has 16 SPL partners with over 95 development programs, of which more than 15% are in clinical stages [10][58] - There is strong demand for MaxCyte's products, with no observed weakness in customer demand despite market fluctuations [9] Company Strategy and Development Direction - MaxCyte is focused on investing in its commercial teams and expanding in-house manufacturing capabilities to support growth in the cell therapy market [11][12] - The company aims to maintain its position as a leader in cell-engineering technology and is exploring opportunities for mergers and acquisitions within the cell-engineering space [22][45] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for SPL partners to generate significant revenue from clinical progress and commercialization over the next 12 to 24 months [11] - The company is cautiously optimistic about the remainder of 2022, expecting core business revenue to grow at least 25% compared to 2021 [17] Other Important Information - Total cash and cash equivalents were reported at $246 million with no debt as of the end of Q1 2022 [16] - Investments in a new headquarters are expected to total approximately $12 million in 2022 [17] Q&A Session Summary Question: What diversity of cell types and molecules are being seen in recent therapies? - Management noted an increase in the diversity of cell populations and more complex edits being performed, with a focus on various T cell subsets and emerging areas like inherited diseases and autoimmune diseases [20][21] Question: Has the approach towards M&A changed due to market conditions? - Management indicated that while there is movement in private financing, they are not seeing a reduction in demand for their products and are focused on solving significant pain points in the cell therapy field [22] Question: Can you provide updates on the VLx product roadmap? - The VLx product is expected to be released in Q4 2022, with a focus on large-scale bioprocessing and rapid production of monoclonal antibodies [23][24] Question: Are there any changes in customer prioritization of pipelines? - Management stated that they are not seeing significant changes in customer prioritization, with strong core business growth indicating continued progress [28] Question: How is hiring progressing in the current competitive environment? - The company is successfully hiring despite a competitive environment, although it may take longer to find suitable candidates [32] Question: What is the opportunity in European and Asian Pacific markets? - Management highlighted strong growth in Europe and ongoing efforts to establish a sustainable presence in Asia, particularly in Japan and China [53]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2021 Earnings Conference Call March 22, 2022 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Doug Doerfler - President and Chief Executive Officer Amanda Murphy - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Julie Simmonds - Panmure Gordon Paul Cuddon - Numis Securities Daniel Arias - Stifel Matt Larew - William Blair Max Masucci - Cowen and Company Mark Massaro - BTIG Operator Thank you for standing by. And welcome to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...

M MaxCyte® Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT, MXCN February 2022 are trademarks of MaxCyte, Inc. in the U.S.A. ® ® ® ® TM © 2019 MaxCyte, Inc. All Rights Reserved info@maxcyte.com | www.maxcyte.com ir@maxcyte.com | www.maxcyte.com Disclaimer The content of this document (the "Presentation") has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"), as amended. Reliance on ...

MaxCyte, Inc. (NASDAQ:MXCT) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Douglas Doerfler - Chief Executive Officer Amanda Murphy - Chief Financial Officer Conference Call Participants Julie Simmonds - Panmure Gordon Max Masucci - Cowen & Company Evan Stampler - Stifel Matthew Larew - William Blair Vidyun Bais - BTIG Jacob Johnson - Stephens Sean Menarguez Good afternoon, everyone. My name is Sean Menarguez, and I'm an analyst on the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 333-257810 MaxCyte, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

MaxCyte, Inc. (NASDAQ:MXCT) Q2 2021 Earnings Conference Call September 13, 2021 4:30 PM ET Company Participants Sean Menarguez - IR Doug Doerfler - CEO Amanda Murphy - CFO Conference Call Participants Julie Simmonds - Panmure Gordon Max Masucci - Cowen & Co. Dan Arias - Stifel Matt Larew - William Blair Mark Massaro - BTIG Jacob Johnson - Stephens, Inc. Sean Menarguez Good afternoon, everyone. Thank you all for participating in today's conference call. On the call for MaxCyte, we have Doug Doerfler, Chief E ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 333-257810 MaxCyte, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...